NIM
CPRX

NEOS Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

NEOS Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,352
Closed -$246K – 636
2025
Q2 		$246K Hold
11,352
– – ﹤0.01% 597
2025
Q1 		$275K Hold
11,352
– – 0.01% 560
2024
Q4 		$237K Hold
11,352
– – 0.01% 572
2024
Q3 		$226K Hold
11,352
– – 0.01% 562
2024
Q2 		$176K Hold
11,352
– – 0.01% 562
2024
Q1 		$181K Buy
+11,352
New +$171K 0.01% 557

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NEOS Investment Management's CPRX Position: Q3 2025 in Review

NEOS Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 11,352 shares — an estimated $246K sold.

NEOS Investment Management first reported a position in CPRX in Q1 2024 and held it in 6 quarters. The position peaked at $275K in Q1 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • NEOS Investment Management reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • NEOS Investment Management sold 11,352 Catalyst Pharmaceutical shares in Q3 2025, an estimated $246K.
  • NEOS Investment Management first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 6 quarters.
  • NEOS Investment Management's Catalyst Pharmaceutical position peaked at $275K in Q1 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on NEOS Investment Management's 13F filing for Q3 2025, filed 7 Nov 2025.